Andrej Dukát, Eliška Kubíková, Milan Kriška, Juraj Payer, František Šimko
The role of LDL-cholesterol as the risk factor of cardIovascular atherosclerosis is in the evidence-based knowledge
well established. How much one should lower this risk factor safely remains an open question. During our educational
meetings some physicians repeatedly questioned their safety, however the proper answer was still lacking. Recently
finished study FOURIER with evolocumab lasted of median 2,2 years with 25 982 patients published a respecified
secondary analysis, bringing the answer to this open question. Multivariable modelling to adjust for baseline factors
associated with achieved LDL-cholesterol showed a monotonic relationship less than 0,2 mmol/l concentrations.
Study results support further LDL-cholesterol lowering in patients with cardiovascular disease to well below current